Skip to main content
Premium Trial:

Request an Annual Quote

Chris van Ingen, Ulf Jonsson

Premium
Chris van Ingen, president of Agilent’s Bio-Analytical Measurement business, will retire on Oct. 31, the last day of the company’s fiscal year, Agilent announced last month. Van Ingen, 61, has been at Agilent and Hewlett Packard, which Agilent was originally part of, for 30 years. He joined HP in 1977 as a sales engineer in the Netherlands and was appointed to his current position in May 2001. No replacement has been named.
 

 
Lumera said this week that Ulf Jonsson, former CEO of Biacore, and Jim Richey, CEO of Auguron Biosciences, have joined the board of directors of Plexera Bioscience, its recently created proteomics subsidiary.
 
Jonsson was one of the three founders of Biacore, which spun out of Pharmacia Biosensor in 1987. GE Healthcare acquired Biacore in 2006
 
Richey is co-founder, president, and CEO of Auguron Biosciences, a protein array spin out of Harvard Medical School. He has held senior executive positions in several biotechnology firms including LJL BioSystems (acquired by Molecular Devices), PerSeptive BioSystems (acquired by Applied Biosystems), Pharmacia Biosensor (acquired by GE Healthcare), and Pharmacia Biotech (acquired by Amersham).

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.